A modified γ-retrovirus vector for X-linked severe combined immunodeficiency

New England Journal of Medicine

Volumn 371, Issue 15, 2014, Pages 1407-1417

  Hacein Bey Abina, Salima ^a,d,e   Pai, Sung Yun ^j,l,m   Gaspar, H Bobby ^p,q   Armant, Myriam ^l,m   Berry, Charles C ^r   Blanche, Stephane ^b,f   Bleesing, Jack ^a,s   Blondeau, Johanna ^d,f,g   De Boer, Helen ^j   Buckland, Karen F ^q   Caccavelli, Laure ^a,d,f,g   Cros, Guilhem ^b   De Oliveira, Satir ^t   Fernández, Karen S ^v   Guo, Dongjing ^j,l   Harris, Chad E ^j   Hopkins, Gregory ^j   Lehmann, Leslie E ^j,l,m   Lim, Annick ^h   London, Wendy B ^j,l,m   Van Der Loo, Johannes C M ^s   Malani, Nirav ^w   Male, Frances ^w   Malik, Punam ^s   Marinovic, M Angélica ^x   McNicol, Anne Marie ^q   Moshous, Despina ^b,f   Neven, Benedicte ^b,f   Oleastro, Matías ^y   Picard, Capucine ^b,c,f   Ritz, Jerome ^l,m,n   Rivat, Christine ^q   Schambach, Axel ^z   Shaw, Kit L ^u   Sherman, Eric A ^w   Silberstein, Leslie E ^l,m   Six, Emmanuelle ^f,g   Touzot, Fabien ^b,d,g   Tsytsykova, Alla ^l,m   Xu Bayford, Jinhua ^p   Baum, Christopher ^z   Bushman, Frederic D ^w   Fischer, Alain ^b,f,g,i   Kohn, Donald B ^t   Filipovich, Alexandra H ^s   Notarangelo, Luigi D ^k,m,o   Cavazzana, Marina ^a,d,f,g   Williams, David A ^j,l,m   Thrasher, Adrian J ^p,q   more..

^a Viral Immunopathology Laboratory   (France)

^b Immunology and Pediatric Hematology   (France)

^c Centre D'Étude des Déficits Immunitaires   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Centre National de la Recherche Scientifique   (France)

^f IMAGINE INSTITUTE   (France)

^g INSERM   (France)

^h INSTITUT PASTEUR   (France)

ⁱ l'alimentation et l'Environnement   (France)

^j Beth Israel Deaconess Medical Cener   (United States)

^k Division of Immunology   (United States)

^l BOSTON CHILDREN S HOSPITAL   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

^o Manton Center for Orphan Disease Research   (United States)

^p Manton Center for Orphan Disease Research ^*  (United States)

^q UNIVERSITY COLLEGE LONDON   (United Kingdom)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^t MATTEL CHILDREN S HOSPITAL   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v UNIVERSITY OF ILLINOIS   (United States)

^w UNIVERSITY OF PENNSYLVANIA   (United States)

^x CLÍNICA SANTA MARÍA   (Chile)

^y HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^z HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA; RETROVIRUS VECTOR; SELF INACTIVATING GAMMA RETROVIRUS VECTOR; UNCLASSIFIED DRUG; CD34 ANTIGEN; COMPLEMENTARY DNA;

ADENOVIRUS INFECTION; ARTICLE; BONE MARROW; CD34 SELECTION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FOLLOW UP; HUMAN; MALE; T LYMPHOCYTE; UNITED STATES; VIRAL GENE THERAPY; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; INFANT; MOUSE; MULTICENTER STUDY; MUTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; RETROVIRUS; TRANSGENE;

ANIMALS; ANTIGENS, CD34; DNA, COMPLEMENTARY; GAMMARETROVIRUS; GENE EXPRESSION; GENE SILENCING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INFANT; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MALE; MICE; MUTATION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSGENES; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84907880404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1404588     Document Type: Article

References (37)

1. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73: 147-57.
2. Puck JM, Deschênes SM, Porter JC, et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 1993; 2: 1099-104.
3. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2: 1366-9.
4. O'Reilly RJ, Dupont B, Pahwa S, et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977; 297: 1311-8.
5. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61: 341-8.
6. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340: 508-16.
7. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002; 99: 872-8.
8. Antoine C, Müller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003; 361: 553-60.
9. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126: 602-10.
10. Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res 2011; 49: 25-43.
11. Brown L, Xu-Bayford J, Allwood Z, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: The case for newborn screening. Blood 2011; 117: 3243-6.
12. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669- 72.
13. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-93.
14. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-7.
15. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-64.
16. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for Xlinked severe combined immunodeficiency. Sci Transl Med 2011; 3: 97ra79.
17. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-9.
18. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-50.
19. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-42.
20. Thornhill SI, Schambach A, Howe SJ, et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008; 16: 590-8.
21. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-25.
22. van der Loo JCM, Swaney WP, Grassman E, et al. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency. Gene Ther 2012; 19: 872-6.
23. Berry C, Hannenhalli S, Leipzig J, Bushman FD. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2006; 2(11): e157.
24. Berry CC, Gillet NA, Melamed A, Gormley N, Bangham CR, Bushman FD. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 2012; 28: 755-62.
25. Berry CC, Ocwieja KE, Malani N, Bushman FD. Comparing DNA integration site clusters with scan statistics. Bioinformatics 2014; 30: 1493-500.
26. Brady T, Roth SL, Malani N, et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res 2011; 39(11): e72.
27. Deichmann A, Hacein-Bey-Abina S, Schmidt M, et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007; 117: 2225-32.
28. Schwarzwaelder K, Howe SJ, Schmidt M, et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007; 117: 2241-9.
29. Wang GP, Berry CC, Malani N, et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 2010; 115: 4356-66.
30. Hardin JW, Hilbe JM. Generalized estimating equations. Boca Raton, FL: Chapman & Hall/CRC Press, 2003.
31. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001; 57: 120-5.
32. Kustikova O, Fehse B, Modlich U, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-4.
33. Cui K, Zang C, Roh TY, et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009; 4: 80-93.
34. Coffin JM, Hughes SH, Varmus HE. Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1997.
35. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
36. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-58.
37. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminasedeficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012; 120: 3635-46.